PLAINVIEW
COMMAND CENTER

Know any stock in seconds.

Type a ticker — we pressure-test it against live facts, filings, and sentiment.

Moderna, Inc. (MRNA) stock analysis

Moderna, Inc. — Healthcare · Biotechnology carries a Plainview business-quality score of 5.9/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Moderna, Inc. shows trailing revenue of $2.22B, a 17.2% gross margin, net cash of $6.87B, a loss per share of -8.45, valued at about 9.7x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

  • Current Price: $54.49
  • YTD Return: +76.6%
  • Revenue TTM: $2.22B
  • Revenue Trend: YoY +260.2%
  • Gross Margin: 17.2%
  • Net Cash: $6.87B
  • EPS: -8.45
  • P/S Ratio: 9.7x

Compare: MRNA vs UNH · MRNA vs JNJ · MRNA vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, ABBV

🎯 Today's top pickstoday's moversSAMPLE · live scan coming soon
RKLB▲ 6.1%
Neutron test-fire cleared overnight — launch cadence story intact.
HIMS▲ 4.5%
Subscriber beat leaked pre-market — telehealth re-rate building.
NVDA▲ 3.8%
Asia AI-capex headlines overnight — momentum into the open.
👁 Watching · popular
RDW at buy-zone$14.20
ASTS spectrum catalyst▲ 5.2%
MP rare-earth tailwind$31.40
SOFI credit turning$9.80
IONQ quantum momentum▼ 1.4%
🔍 Candidates · early
OKLOACHRTEMRXRXSMRJOBYCLSKTMCSERVBTDR
Got holdings? Sign in to track your portfolio, theses, and catalysts.